Apyx Medical Corp. (APYX) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Apyx Medical Corporation Reports First Quarter 2019 Financial Results and Updates Fiscal Year 2019 Outlook
May 8, 2019 4:05 PM EDTAdvanced Energy Sales of $4.4 million in Q1, up 66% year-over-year
CLEARWATER, Fla.--(BUSINESS WIRE)-- Apyx Medical Corporation (NASDAQ: APYX) (the Company), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion Cosmetic Technology brand in the cosmetic surgery market, today reported financial results for its first quarter ended March31, 2019.
First Quarter 2019 Financial Summary:
Total Q1 revenue from continuing operations of $5.8 million, up 71% year-over-year. Advanced Energy revenue of $4.4 million, up 66% year-over-year.... More